Akorn to Report Fourth Quarter and Full Year 2018 Results
February 11 2019 - 4:38PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it plans to issue a
press release on Thursday, February 28, 2019 outlining
the fourth quarter and full year 2018 results.
In addition, the Company has scheduled a conference call
at 10:00 a.m. ET on the same day to discuss its fourth
quarter and full year 2018 financial results. Hosting the call will
be Douglas Boothe, President and Chief Executive Officer and Duane
Portwood, Chief Financial Officer.
The dial-in number to access the call is (844) 249-9382 in the
U.S. and +1 (270) 823-1530 for international callers. The
conference ID is 4099919. To access the live webcast, please go to
Akorn’s Investor Relations web site
at http://investors.akorn.com.
A webcast replay of the conference call will be available
shortly following the conclusion of the call and will be available
for 90 days following the call. To access the webcast replay,
please go to Akorn’s Investor Relations web site
at http://investors.akorn.com.
Annual MeetingThe Company plans to hold its
2019 annual meeting of shareholders on May 1, 2019, at 10:00 a.m.,
local time, at the Company’s headquarters at 1925 W. Field Ct.,
Suite 300, Lake Forest, IL 60045. The record date for the annual
meeting will be March 8, 2019.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes statements that may
constitute "forward looking statements", including expectations and
other statements regarding Akorn's goals and plans. When used in
this document, the words “will,” “expect,” “continue," “believe,”
“estimate,” “intend,” “could,” and similar expressions are
generally intended to identify forward-looking statements. These
statements are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. A number of
important factors could cause actual results of Akorn and its
subsidiaries to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to: (i) the effect of the Delaware court’s recent decision
against Akorn on Akorn’s ability to retain and hire key personnel,
its ability to maintain relationships with its customers, suppliers
and others with whom it does business, or its operating results and
business generally, (ii) the risk that ongoing or future litigation
related to the court’s decision may result in significant costs of
defense, indemnification and/or liability, (iii) the outcome of the
investigation conducted by Akorn with the assistance of outside
consultants, into alleged breaches of FDA data integrity
requirements relating to product development at Akorn and any
actions taken by Akorn, third parties or the FDA as a result of
such investigations, (iv) the difficulty of predicting the timing
or outcome of product development efforts, including FDA and other
regulatory agency approvals and actions, if any, (v) the timing and
success of product launches, (vi) difficulties or delays in
manufacturing, and (vii) such other risks and uncertainties
outlined in the risk factors detailed in Part I, Item 1A, “Risk
Factors,” of Akorn’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2017 (as filed with the Securities and Exchange
Commission (“SEC”) on February 28, 2018) and in Part II, Item 1A,
“Risk Factors,” of Akorn’s Quarterly Reports on Form 10-Q for the
periods ended March 31, June 30, and September 2018 (as filed with
the SEC on May 2, August 1, and November 6, 2018), and other risk
factors identified from time to time in our filings with the SEC.
Readers should carefully review these risk factors, and should not
place undue reliance on our forward-looking statements. These
forward-looking statements are based on information, plans and
estimates at the date of this report. Akorn undertakes no
obligation to update any forward-looking statements to reflect
changes in underlying assumptions or factors, new information,
future events or other changes.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024